These agents mainly act on serine-threonine kinases, such as Raf-1, and on receptor tyrosine kinases, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor-β (PDGFR-β), resulting in deficient tumor-related microvascular angiogenesis and proliferation of tumor cells. The gene discussed is MARK2; the disease is neoplasm.